NEWS & INSIGHTS

October 2022 heralded another crisis for hospitals and physicians: the tripledemic. It likely won’t be the last season for a potential infectious disease calamity, so every healthcare stakeholder must play a role in mitigating the damage. However, issues such as staffing, vaccine fatigue, misinformation, and operational challenges may inhibit successful interventions. Precision’s Maureen Hennessey and Cynthia Miller argue for the need to create a wholistic pandemic strategy that align’s with the Quintuple Aim and supports the five aims: care-team well being, better patient care, healthier people, affordability, and health equity.

READ THE ARTICLE HERE!

New study demonstrates the feasibility of systematically integrating long-term survival estimates obtained from a formal expert elicitation study with empirical clinical trial data through a case study.

Learn more about recent work of PRECISIONheor’s Shannon Cope (co-primary author), Kevin Towle and Ali Mojebi and their co-authors HERE! 

As new channels enter the healthcare conversation mix, engagement strategies are changing. Social media, previously an incremental investment for pharma, is now foundational. Precision’s Christian Rodgers, SVP, Social Media, explains why in “Zoom star replaced the podium star” in Pharmaceutical Executive.

READ THE ARTICLE HERE!

HEOR data can help to close knowledge gaps and uncertainties that payers may possess when making decisions involving access and reimbursement. Precision’s Jacquelyn Chou, Alexandria Portelli and Andrew Cournoyer discuss important steps in prelaunch HEOR planning to support a successful market launch.

READ THE ARTICLE HERE!

Data and analytics can help drive and inform launch preparations and support efforts to achieve launch excellence through realistic goal-setting and risk mitigation. PRECISIONadvisors works with manufacturers, helping them make key decisions—related to product positioning, go-to-market strategy, and customer engagement across payers, providers, prescribers, and patients—through data- and analytics-driven insights.

Learn how an integrated data-driven approach can set realistic goals and de-risk your launch.

DOWNLOAD THE WHITEPAPER HERE!

More and more genetic tests are coming onto the market to help make sure the right patient gets the right drug at the right time. However, the sheer volume of these tests may be overwhelming payers in their coverage decisions. Precision’s Erin Lopata and others weigh in on the need for shareholders to work together to help establish the clinical utility that payers need to make coverage decisions on genetic tests.

READ THE ARTICLE HERE!

Precision’s Jenny Love and other industry insiders weigh in on Med Ad New’s “Healthcare Agency Roundtable 2022: Positioning for resiliency: Back to the (virtual) office, building and retaining talent.”

READ THE ARTICLE HERE!

More and more genetic tests are coming onto the market to help make sure the right patient gets the right drug at the right time. However, the sheer volume of these tests may be overwhelming payers in their coverage decisions. Precision’s Erin Lopata and others weigh in on the need for shareholders to work together to help establish the clinical utility that payers need to make coverage decisions on genetic tests.

READ THE ARTICLE HERE!